Page 4 - Dyslipidaemia for programming

REFLECTIONS dae mia

Dyslipidaemia Global Newsletter #3 Dyslipi
Long-term efficacy and safety of moderate-intensity statin with ezetimibe Dyslipi
aim ead
combination therapy versus high-intensity statin monotherapy in patients with

atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-

inferiority trial.
Kim BK, et al. Lancet. 2022 Jul 30;400(10349):380-390.

A reduction in LDL-C concentration has been associated (72% vs. 58% in year three). In addition, discontinuation or
with more favourable clinical outcomes, and the use of statin dose reduction of study medication due to adverse events or
remains the cornerstone of lipid-lowering therapy, especially in intolerance was higher in the high-intensity statin monotherapy
patients with atherosclerotic cardiovascular disease (ASCVD) groups (8.2%) compared to the moderate-intensity statin with
who are at very high risk of cardiovascular diseases. Reducing ezetimibe combination therapy group (4.8%, p<.0001).
LDL-C can be accomplished by increasing the intensity of a
statin monotherapy or using drug combinations with a statin According to the 2019 ESC/EAS dyslipidaemia guidelines,
and ezetimibe. a dual goal of achieving LDL-C concentrations of <55 mg/dL
and LDL-C reduction of =50% from baseline in patients with
In this randomized, open-label, non-inferiority trial of documented ASCVD has been recommended. This may be
3780 patients with ASCVD at 26 clinical centres in South
Korea, patients were randomly assigned to receive either
moderate-intensity statin with ezetimibe combination therapy
(rosuvastatin 10 mg with ezetimibe 10 mg) or high-intensity
statin monotherapy (rosuvastatin 20 mg).

Among patients with documented ASCVD who are at very high
risk of CV diseases, moderate-intensity statin with ezetimibe
combination therapy was non-inferior to high-intensity statin
monotherapy for the three-year composite of CV death, major
CV events, or non-fatal stroke (with a non-inferiority margin of
2.0%).

Regarding secondary endpoints, higher percentages of
patients achieved a LDL-C <70 mg/dL in the moderate-
intensity statin with ezetimibe combination therapy group
compared to the high-intensity statin monotherapy group

TABLE OF CONTENTS